The estimated Net Worth of Life Sciences Holdings Ltd ... is at least $34.3 Milion dollars as of 8 August 2022. Life Ltd owns over 2,150,000 units of Poseida Therapeutics stock worth over $34,323,452 and over the last 3 years Life sold PSTX stock worth over $0.
Life has made over 6 trades of the Poseida Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently Life bought 2,150,000 units of PSTX stock worth $7,525,000 on 8 August 2022.
The largest trade Life's ever made was buying 2,150,000 units of Poseida Therapeutics stock on 8 August 2022 worth over $7,525,000. On average, Life trades about 441,258 units every 44 days since 2021. As of 8 August 2022 Life still owns at least 11,835,673 units of Poseida Therapeutics stock.
You can see the complete history of Life Ltd stock trades at the bottom of the page.
Life's mailing address filed with the SEC is THE LENNOX BUILDING, 50 RICHMOND STREET SOUTH, DUBLIN, IRELAND, L2, D02 FK02.
Over the last 4 years, insiders at Poseida Therapeutics have traded over $7,666,974 worth of Poseida Therapeutics stock and bought 3,065,405 units worth $15,916,632 . The most active insiders traders include David Hirsch, Life Sciences Holdings Ltd ... a Eric Ostertag. On average, Poseida Therapeutics executives and independent directors trade stock every 18 days with the average trade being worth of $303,665. The most recent stock trade was executed by Eric Ostertag on 8 August 2022, trading 142,857 units of PSTX stock currently worth $500,000.
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
Poseida Therapeutics executives and other stock owners filed with the SEC include: